Mammatas, L H <br/><br/>
Sorafenib administered using a high-dose, pulsatile regimen in patients with advanced solid malignancies: a phase I exposure escalation study.  [electronic resource] 

 -  Cancer chemotherapy and pharmacology  05 2020 
 - 931-940 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article 
<br/><br/><label>ISSN: </label>1432-0843 
<br/><br/><label>Standard No.: </label>10.1007/s00280-020-04065-5  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Area Under Curve<br/>Dose-Response Relationship, Drug<br/>Drug Administration Schedule<br/>Drug Monitoring--methods<br/>Drug-Related Side Effects and Adverse Reactions--prevention & control<br/>Female<br/>Humans<br/>Male<br/>Middle Aged<br/>Neoplasms--drug therapy<br/>Protein Kinase Inhibitors--administration & dosage<br/>Pulse Therapy, Drug--methods<br/>Sorafenib--administration & dosage<br/>Treatment Outcome